Freeman, Karoline, Osipenko, Leeza, Clay, Diane, Hyde, Julia and Szczepura, Ala (2007) A review of evidence on non-invasive prenatal diagnosis (NIPD) : tests for fetal RHD genotype. [Report]

Preview	PDF WRAP_Szczepura_RhDreportfinalversion_website_1.pdf - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (595Kb)
	Microsoft Word WRAP_Szczepura_zAccess_Paper_Review_Revised_Send.doc Restricted to Repository staff only Download (125Kb)

Abstract

This report concentrates on three main areas. First and foremost, we set the background context for RhD NIPD in prenatal care. While the methodology chapter describes how the literature review was carried out and how additional information was collected, the second chapter provides an overview of the key issues associated with pregnancy of RhD negative women. We present background information based on publications from 1997 to 2006 which describe the genetic condition and its prevalence (RhD negativity) in populations, as well as the frequency of cases of sensitisation and HDN (haemolytic disease of the newborn). We also discuss current service provision for RhD negative women in a number of European countries and look at how the NIPD test might be set within current service contexts.

Item Type:	Report
Subjects:	R Medicine > RJ Pediatrics
Divisions:	Faculty of Medicine > Warwick Medical School > Clinical Sciences Research Institute (CSRI) Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Prenatal diagnosis, Diagnosis, Noninvasive
Series Name:	Initial report
Publisher:	University of Warwick
Place of Publication:	[Coventry]
ISBN:	0953543064
Date:	January 2007
Number of Pages:	57
Status:	Not Peer Reviewed
Access rights to Published version:	Open Access
Description:	Final version (published as open access)
Funder:	Sixth Framework Programme (European Commission) (FP6)
Grant number:	LSHB-CT-2004-503243 (FP6)
References:	1. Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C, Tappenden P. 2003. A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative HTA V.7, No. 4 2. Wagner FF, Frohmajer A, Flegel WA 2001. RHD positive haplotypes in D negative Europeans. BMC Genetics 2:10. PubMed 3. Contreras M. 1998. Prevention of Rh haemolytic disease of the fetus and newborn – general background. British J. of Obstetrics and Gynaecology; 105: 7-10. PubMed 4. Simpson JL, Elias S. 1993. Isolating fetal cells from maternal blood. Advances in prenatal diagnosis through molecular technology. JAMA 271(14): 1079-1080. PubMed 5. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS. 1997 Presence of fetal DNA in maternal plasma and serum. The Lancet 350: 485-487. PubMed 6. Cunningham J, Yates Z, Hamlington J, Mason G, Mueller R, Miller D. 1999. Non-invasive RNA-based determination of fetal Rhesus D type: a prospective study based on 96 pregnancies. Brit. J. of Obstet Gynaecol 106: 1023-8. PubMed 7. NICE 2002. Technology appraisal 41: Routine anti-D prophylaxis for pregnant women who are RhD negative. Available online at [http://www.nice.org.uk/page.aspx?o=31679]. Accessed on November 20, 2005. 8. Turner MJ, Martin CM, O'Leary JJ. 2003. Detection of fetal Rhesus D gene in a whole blood of women booking for routine prenatal care. European J. of Obstetrics and Gynecology and Reproductive Biology 108: 29-32. 9. Siva SC, Johnson SI , Mccracken SA, Morris JM. 2003. Evaluation of the clinical usefulness of isolation of fetal DNA from the maternal circulation. Aust N Z J Obstet Gynaecol 43(1): 10-15. PubMed 10. Lo YM. 1998. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for non-invasive prenatal diagnosis. Am J Hum Genet. 62 (4): 768-775. PubMed 11. Bonsel, G. et al. 2005 ZonMw. Final Report Health Care Efficiency Research Programme on http://www.zonmw.nl. 12. Szczepura A, Freeman K, Osipenko L. 2005. Emerging Prenatal Genetic Tests: Developing a Health Technology Assessment (HTA) Framework for Informed Decision-making. ISBN 0-9535430-5-6. 13. Moise KJ. 2005. Fetal RHD typing with free DNA in maternal plasma. American Journal of Obstetrics and Gynecology 192: 663-665 PubMed 14. Westhoff CM. 2004. The Rh blood group system in review: A new face for the next decade. Transfusion 44: 1663-1673. PubMed 15. Baptista-González HA, Rosenfeld-Mann F, Leiss-Marquez T. 2001. Prevention of maternal RhD isoimmunization with anti-D gamma globulin. Salud Publica de Mexico 43(1): 1-6. 16. US Preventive Services Task Force. 1996 Guide to Clinical Preventive Services, 2nd edition, Washington, DC: U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. 17. MacKenzie I, Bichler J, Mason G, Lunan C, Stewart P, Al A. 2004. Efficacy and safety of a new, chromatographically purified rhesus(D) immunoglobulin. European Journal of Obstetrics and Gynecology and Reproductive Biology 117:154-161. PubMed A Review of Evidence on Non-invasive Prenatal Diagnosis (NIPD): Tests for Fetal RHD Genotype 45 18. Moise KJ. 2004. Grand Rounds: Rh disease: It’s still a threat. Contemporary Ob/Gyn 49: 34-48. 19. Whitfield CR, Raafat A, Urbaniak SJ. 1997. Underreporting of mortality from RhD haemolytic disease in Scotland and its implications: retrospective review. BMJ 315: 1504-1505. PubMed 20. Chavez GF, Mulinare J, Edmonds LD. 1991. Epidemiology of Rh hemolytic disease of the newborn in the United States. JAMA 265(24): 3270-4. PubMed 21. Moise JM. 2002. Management of rhesus alloimmunization in pregnancy. Obstetrics and Gynecology 100(3): 600-611. PubMed 22. Craig S, Morris K, Tubman T. 2000. The fetal and neonatal outcomes of Rhesus D antibody affected pregnancies in Northern Ireland. Ir Med J. 93(1):17-18. PubMed 23. De Vrijer B, Harthoorn-Lasthuizen EJ, Oosterbaan HP. 1999. The incidence of irregular antibodies in pregnancy: a prospective study in the region of the ‘s-Hertogenbosch. Ned Tijdschr geneeskd. 143(50): 2523-2527. PubMed 24. Ulm B, Svolba G, Ulm MR, Bernaschek G, Panzer S. 1999. Male fetuses are particularly affected by maternal sensitisation to D antigen. Transfusion 39(2): 169-173. PubMed 25. van Kamp IL, Klumper FJ, Bakkum RS, Oepkes D, Meerman RH, Scherjon SA, Kanhai HH. 2001. The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatment. Am J Obstet Gynecol. 185(3): 668-673. PubMed 26. Whitecar PW, Farb, R, Subramanyam L, Dorman K, Balu RB, Moise KJ Jr. 2002. Paternal leukocyte alloimmunization as a treatment for hemolytic disease of the newborn in a rabbit model. Am J Obstet Gynecol. 187(4): 977-980. PubMed 27. Lam GK, Subramanyam L, Orton S, Farb R, Moise KJ Jr. 2003. Minimizing red blood cell contamination while isolating mononuclear cells from whole blood: the next step for the treatment of severe hemolytic disease of the fetus/newborn. American Journal of Obstetrics and Gynecology. 189 (4): 1012-1016. PubMed 28. Finning KM, Martin PG, Soothill PW, Avent ND. 2002. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 42:1079-1085. PubMed 29. Jones ML, Wray J, Wight J, Chilcott J, Forman K, Tappenden P, Jones CB. 2004. A review of the clinical effectiveness of routine prenatal anti-D prophylaxis for rhesus-negative women who are pregnant. BJOG 111: 892-902. PubMed 30. Urbaniak SJ. 1998. The scientific basis of prenatal prophylaxis. Br J Obstet Gynecol. 105 (Suppl 18): 11-18. 31. Scott ML. 2001. Monoclonal anti-D for immunoprophylaxis. Vox Sanguinis 81:213-218 PubMed 32. Crowther CA, Middleton P. 2005. Anti-D administration in pregnancy for preventing Rhesus sensitisation. The Cochrane Database of Systematic Reviews Issue 2: 1-13. 33. Symphogen A/S and Cambridge Antibody Technology sign patent licensing agreement. Available online at [www.symphogen.com]. 34. Medicon Valley Academy: Symphogen and Biovitrum enter into a collaboration for scale-up and production of clinical material for a recombinant polyclonal anti-D antibody preparation: www.mva.org). 35. AGM presentation 2003. Available online at [www.csl.com.au]. 36. AAR (Allens Arthur Robinson): Life Therapeutics negotiate rights for UK recombinant therapeutic. Available online at [www.aar.com.au]. A Review of Evidence on Non-invasive Prenatal Diagnosis (NIPD): Tests for Fetal RHD Genotype 46 37. Miescher S, Zahn-Zabal M, De Jesus M, Moudry R, Fisch I, Vogel M, Kobr, M, Imboden MA, Kragten E, Bichler J, Mermod N, Stadler BC, Amstutz, H, Wurm F. 2000. CHO expression of a novel human recombinant IgG1 anti-RhD antibody isolated by phage display. British Journal of Haematology 111: 157-166. PubMed 38. Zamerowski S, Lumley M, Arreola RA , Dukes K, Khan A, Sullivan L. 1999. The psychosocial impact on high-risk pregnant women of a noninvasive prenatal diagnostic test. Fetal Diagnosis and Therapy 14: 125-126. PubMed 39. Lo YM, Bowell PJ, Selinger M, Mackenzie IZ, Chamberlain P, Gillmer MD, Elliott P, Pratt G, Littlewood TJ, Fleming KA . 1994. Prenatal determination of fetal rhesus D status by DNA amplification of peripheral blood of rhesus-negative mothers. Ann N Y.Sci 731: 229-236. PubMed 40. Tufan NLS, Tufan AC, Kalei B, Yildrim B, Semerci CN, Bagci H. 2005. Analysis of cell-free fetal DNA from maternal plasma and serum using a conventional multiplex PCR: Factors influencing success. Turk J Med Sci. 35: 85-92. 41. Houfflin-Debarge V, Delsalle A, Subtil D, Mannessier L, Codaccioni X, Puech F. 2000. High sensitivity of fetal DNA in plasma compared to serum and nucleated cells using unnested PCR in maternal blood. Fetal Diagnosis and Therapy 15(2): 102-107. PubMed 42. Tungwiwat W, Fucharoen G, Ratanasiri T, Sanchaisuriya K, Fucharoen S. 2003. Non-invasive fetal sex determination using a conventional nested PCR analysis of fetal DNA in maternal plasma. Clinica Chimica Acta 334: 173-177. PubMed 43. Finning K, Daniels G, and Martin P. 2003. Detection of fetal Rhesus D gene in whole blood of women booking for routine prenatal care. Eur J Obstet Gynecol Reprod Biol. 110:117. PubMed 44. Rouillac-Le Sciellour C, Puillandre P, Gillot R, Baulard C, Metral S, Le Van Kim C, Cartron JP, Colin Y, Brossard Y 2004. Large-scale pre-diagnosis study of fetal RHD genotyping by PCR on plasma DNA from RhD-negative pregnant women. Mol Diagn. 8(1): 23-31. PubMed 45. Johnson L, McCracken SA, Morris JM, Woodland NB , Flower RL. 2003. Variation in the reliability of RHD prenatal genotyping using the polymerase chain reaction and targeting multiple exons of the RHD gene. Vox Sanguinis 85: 222-223. PubMed 46. Randen I, Hauge R, Kjeldsen-Kragh J, Fagerhol MK. 2003. Prenatal genotyping of RHD and SRY using maternal blood. Vox Sanguinis 85: 300-306. PubMed 47. Zhong XY, Holzgreve W, Hahn S .2001. Risk free simultaneous prenatal identification of fetal Rhesus D status and sex by multiplex real-time PCR using cell free fetal DNA in maternal plasma. Swiss Med Wkly 131 (5-6): 70-74. PubMed 48. Gonzalez-Gonzalez C, Garcia-Hoyos M, Trujillo-Tiebas MJ, Lorda-Sanchez I, de Alba, MR Infantes F, Gallego J, Diaz-Recasens J, Ayuso C, Ramos C, 2005. Application of fetal DNA detection in maternal plasma: a prenatal diagnosis unit experience. J. Histochem Cytomchem 53 (3): 307-14. PubMed 49. van der Schoot CE, Tax GH, Rijnders R J, de Haas M, Christiaens GC. 2004. Screening for foetal RHD-genotype by plasma PCR in all D-negative pregnant women is feasible. Vox Sang 87 (Suppl3): Abstract (Tu07.04). 50. Aubin J-T, Le Van Kim C, Mouro I, Colin Y, Bignozzi C, Brossard Y, Aubin J-PC. 1997. Specificity and sensitivity of RHD genotyping methods by PCR-based DNA amplification. British Journal of Haematology 98: 356-364. PubMed A Review of Evidence on Non-invasive Prenatal Diagnosis (NIPD): Tests for Fetal RHD Genotype 47 51. Liu W, Avent ND, Jones JW, Scott ML, Voak D. 1999. Molecular configuration of Rh D epitopes as defined site-directed mutagenesis and expression of mutant Rh constructs in K562 erythroleukemia cells. Blood 94 (12): 3986-3996. PubMed 52. Avent ND, Liu W, Jones JW, Scott ML, Voak D, Pisacka M, Watt J, Fletcher A. 1997. Molecular analysis of Rh transcripts and polypeptides from individuals expressing the DVI variant phenotype: an RHD gene deletion event does not generate all DVI ccEe phenotypes. Blood 89 (5): 1779-1786. PubMed 53. Mota M, Fonseca N, Kutner JM, Rosenblit J, Castilho L. 2004. Alloanti-D immunisation by weak D type 1 RBCs. Vox Sang. 87 (Suppl.3) Abstract: (A18.16). 54. Daniels G, Finning K, Martin P. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang. 87: 225-232. PubMed 55. Scott ML. 2004. The complexities of the Rh system. Vox Sang. 87 (Suppl. 1): S58-S62. PubMed 56. Avent ND. 2005. High variability of the RH locus in different ethnic backgrounds. Transfusion 45: 293-294. PubMed 57. Cherif-Zahar B, Raynal V, Le Van Kim C, D'Ambrosio AM, Bailly P, Cartron JP, Colin Y. 1993. Structure and expression of the RH locus in the Rh-deficiency syndrome. Blood 82:656-662. PubMed 58. Hromadnikova I, Vechetova L, Vesela K, Benesova B, Doucha J, Kulovany E, Vlk R. 2005. Non-invasive fetal RHD exon 7 and exon 10 genotyping using real-time PCR testing of fetal DNA in maternal plasma. Fetal Diagn Ther 20(4): 275-280. PubMed 59. Hromadnikova I, Vesela K, Benesova B, Nekovarova K, Duskova D, Vlk R, Spalova I, Gerychova R, Hakenova A, Rosenbaumova Z, Vlasin P, Vlachova A,Palasek V, Roznakova E, Calda P. 2005. Non-invasive fetal RHD and RHCE genotyping from maternal plasma in alloimmunized pregnancies. Prenatal Diagnosis 25 (12): 1079-1083. PubMed 60. Gautier E, Benachi A, Giovangrandi Y, Ernault P, Olivi M, Gaillon T, Costa JM. 2005. Fetal RHD genotyping by maternal serum analysis: a two year experience. American Journal of Obstetrics and Gynecology 192: 666-9. PubMed 61. Bischoff FZ, Nguyen DD, Marquez-Do D, Moise KJ Jr, Simpson JL, Elias S Bischoff ES. 1999. Noninvasive determination of fetal RhD status using fetal DNA in maternal serum and PCR. J of Social Gynecol Investig 6: 64-9. PubMed 62. Nelson M, Eagle C, Langshaw M, Popp H, Kronenberg H. 2001. Genotyping fetal DNA by non-invasive means: extraction from maternal plasma Vox Sang 80: 112-116. PubMed 63. Costa JM, Giovangrandi Y, Ernault P, Lohmann L, Nataf V, El Halali N, Gautier E. 2002. Fetal RHD genotyping in maternal serum during the first trimester of pregnancy. Brit J. of Haem 119: 255-260. PubMed 64. Legler TJ, Lynen R, Maas JH, Pindur G, Kulenkampff D, Suren A, Osmers R,Kohler M. 2002. Prediction of fetal RhD and Rh CcEe phenotype from maternal plasma with real-time PCR. Transfus Apheresis Sci, 27(3): 217-23. 65. Hromadnikova, I Vechetova, L. Vesela, K. Benesova, B.Doucha, J.Vlk, R. 2005. Non-invasive Fetal RHD and RHCE Genotyping using real-time PCR testing of maternal plasma in RhD negative pregnancies. Journal of Histochemistry and Cytochemistry 53(3): 301-5. PubMed A Review of Evidence on Non-invasive Prenatal Diagnosis (NIPD): Tests for Fetal RHD Genotype 48 66. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, Bossuyt PM 2005. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA. 282 (11): 1061-1066. PubMed 67. Finning K, Martin P, Daniels G. 2004. A clinical service in the UK to predict fetal Rh (Rhesus) D blood group using free fetal DNA in maternal plasma. Ann NY Acad Sci 1022: 119-123. PubMed 68. Tabor A, Bang J, Norgaard-Pedersen B. 1987. Feto-maternal haemorrhage associated with genetic amniocentesis: results of a randomised trial. Br J Obstet Gynaecol. 94: 528-534. PubMed 69. Murray JC, Karp LE, Williamson RA, Cheng EY, Luthy DA. 1983. Rh isoimmunisation related to amniocentesis. Am J Med Genet. 16: 527-534. 70. Daniels G, van der Schoot CE, Olsson ML. 2005. Report of the first international workshop on molecular blood group genotyping. Vox Sanguinis 88: 136-142. PubMed 71. Johnson KL, Dukes KA, Vidaver J, LeShane ES, Ramirez I, Weber WD, Bischoff, FZ, Hahn S, Sharma A, Dang DX, Hire LM, Bianchi DW, Simpson JL, Holzgreve W,Elias S, Klinger KW. 2004. Interlaboratory comparison of fetal male DNA detection from common maternal plasma samples by real-time PCR. Clinical Chemistry 50(3): 516-521. PubMed 72. Bianchi DW, Avent ND, Costa JM, van der Schoot CE. 2005. Noninvasive prenatal diagnosis of fetal rhesus D. Ready for Prime(r) time. Obstetrics and Gynecology. 106(4): 841-844. PubMed 73. STARD checklist. Available online at [http://www.consort-statement.org/stardstatement.htm]. 74. SAFE NoE Meeting in Göttingen, Germany. June 16, 2005. 75. Guz K, Brojer E, Zupanska B, Orzinska A, Kalinska A, Bec JR. 2004. Non-invasive foetal RhD typing and RhD negative pregnant women - prelim. Observations. Ginekol Pol 75: 21-5. 76. Harper TC, Finning KM, Martin P, Moise KJ Jr. 2004. Use of maternal plasma for non-invasive determination of foetal RhD status. American J. of Obstet & Gyn 191: 1730-2. PubMed 77. Goldberg, C. Test reveals gender early in pregnancy. The Boston Globe. Available at: www.boston.com/yourlife/health/women/articles/2005/06/27/test_reveals_gender_early_in_pregnancy/ 78. Baby Gender Mentor™ Home DNA Gender Testing Kit: http://www.pregnancystore.com/baby_gender_mentor.htm 79. Kaiser J. 2005. An earlier look at baby’s genes. Science 309: 1476-1478. PubMed 80. 23 October 2005 Kit said I’d have a boy…but my tot’s a girl. The Sunday Mail. Available at: www.sundaymail.co.uk/news 81. Genetest Corporation. Non-invasive prenatal DNA testing services. www.genetestlabs.com/ prenatal/prenatalinformation.htm 82. Hall AM, Cairns LS, Altmann DM, Barker RN, Urbaniak SJ. 2005. Immune response and tolerance to the RhD blood group protein in HLA-transgenic mice. Blood 105 (5): 2175-2179. PubMed 83. Van den Veyver IB, Chong SS, Cota J, Bennett PR, Fisk NM, Handyside AH,Cartron JP, Le Van Kim C, Colin Y, Snabes MC. 1995. Single-cell analysis of the RhD blood type for use in preimplantation diagnosis in the prevention of severe haemolytic disease of the newborn. Am J Obsts Gynecol. 172: 533-540. PubMed A Review of Evidence on N
URI:	http://wrap.warwick.ac.uk/id/eprint/129

Request changes to a record

Actions (login required)

View Item